The melanocortin 4 receptor agonist setmelanotide is now FDA approved for weight management in adults and children with ...

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) announced that the U.S. Food and Drug Administration has approved IMCIVREE ...

The U.S. Food and Drug Administration expanded the use of Rhythm Pharmaceuticals’  therapy for a rare form of obesity ​caused ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and ...

The FDA has approved an expanded indication for setmelanotide to treat children and adults with acquired hypothalamic obesity, Rhythm Pharmaceuticals announced. Setmelanotide (Imcivree, Rhythm ...

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

The U.S. Food and Drug Administration (FDA) on Thursday approved an expanded indication for Rhythm Pharmaceuticals Inc.’s RYTM Imcivree (setmelanotide) to treat acquired hypothalamic obesity (HO). The ...

At its peak, Imcivree’s sales in hypothalamic obesity could reach over $2 billion worldwide, according to analysts at Stifel.

Please provide your email address to receive an email when new articles are posted on . Setmelanotide was linked to reduction in BMI at 52 weeks compared with placebo for patients with acquired ...

The prevalence of obesity is steadily rising and has huge health and financial implications for society. Weight gain is due to an imbalance between dietary intake and energy expenditure and research ...

LAS VEGAS -- Obese patients who continue to have "thyroid symptoms" even when their levels are normalized may have a hypothalamic dysfunction, researchers reported here. In a single-center study of 50 ...